Oct 1, 2024 | Genomics, Kurt Harden, News, Nutrigenomics, Pharmacies, Pharmacogenomics, Wellness
MedBen Chairman & CEO Kurt Harden and Profero Team Director of Precision Medicine Cynthia Yu were featured presenters at the 11th Annual Sherrill-Morgan Healthcare Innovation Conference on September 18th. Harden and Yu spoke on the topic of genomic testing — what...
Jul 23, 2024 | Federal Trade Commission (FTC), Formularies, News, Pharmacy Benefits Manager (PBM)
In an interim report released on July 9, the Federal Trade Commission charges major pharmacy benefit managers of engaging in business practices designed to benefit their own bottom lines at the expense of clients. The FTC report, subtitled “The Powerful...
Jul 5, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Feb 6, 2024 | Claims, Cost Savings, Drug costs, Gene therapy, Genetic testing, MedBen Rx, MedBen University, News, Pharmacogenomics, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs
MedBen recently had the honor to welcome some of the most respected names in the benefits management industry. At the invitation-only 2024 Benefits Advisory Conference on January 26, attending brokers learned about health plan innovations that will help self-funded...
Sep 29, 2023 | Announcements, Biosimilar, Humira, MedBen Rx, News, Perigon Pharmacy 360, Ventegra
Here’s some cost-saving news for MedBen Rx clients who use Ventegra as their processor. On July 1, 2023, biosimilar products were released for the popular and expensive anti-inflammatory therapy, Humira. A 30-day supply of Humira, which is used to treat a variety of...
Jan 6, 2023 | Comparative Effectiveness, Cost Plus Pricing, MedBen Rx, News, Prescription drugs, Rx Costs, Rx prices, Specialty Drugs
From Reuters: “Drugmakers including Pfizer Inc, GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research...
